Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Organon & Co (OGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: OGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $14
1 Year Target Price $14
| 0 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 2 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 10.57% | Avg. Invested days 52 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.53B USD | Price to earnings Ratio 3.38 | 1Y Target Price 14 |
Price to earnings Ratio 3.38 | 1Y Target Price 14 | ||
Volume (30-day avg) 7 | Beta 0.55 | 52 Weeks Range 8.01 - 22.24 | Updated Date 07/8/2025 |
52 Weeks Range 8.01 - 22.24 | Updated Date 07/8/2025 | ||
Dividends yield (FY) 0.83% | Basic EPS (TTM) 2.88 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.92% | Operating Margin (TTM) 21.48% |
Management Effectiveness
Return on Assets (TTM) 6.98% | Return on Equity (TTM) 254.24% |
Valuation
Trailing PE 3.38 | Forward PE 5.03 | Enterprise Value 10935772932 | Price to Sales(TTM) 0.4 |
Enterprise Value 10935772932 | Price to Sales(TTM) 0.4 | ||
Enterprise Value to Revenue 1.74 | Enterprise Value to EBITDA 7.38 | Shares Outstanding 259956000 | Shares Floating 258734270 |
Shares Outstanding 259956000 | Shares Floating 258734270 | ||
Percent Insiders 0.24 | Percent Institutions 80.89 |
Upturn AI SWOT
Organon & Co
Company Overview
History and Background
Organon & Co. was formed in 2021 as a spin-off from Merck & Co. (MRK). It focuses on women's health, biosimilars, and established brands. Organon inherited a portfolio of products and a global footprint.
Core Business Areas
- Women's Health: Focuses on contraception, fertility treatments, and other therapies for women. Includes products like Nexplanon and NuvaRing (divested).
- Biosimilars: Develops and commercializes biosimilar versions of established biologic drugs, covering areas such as immunology and oncology.
- Established Brands: A broad portfolio of well-known, off-patent pharmaceutical products across various therapeutic areas including respiratory, cardiovascular, and dermatology.
Leadership and Structure
Organon is led by Kevin Ali (CEO). The company operates with a global organizational structure, focusing on commercial execution and business development.
Top Products and Market Share
Key Offerings
- Nexplanon: A long-acting reversible contraceptive implant. Market share is significant in the US long-acting reversible contraceptive market. Competitors include intrauterine devices (IUDs) like Mirena (BAYRY) and Skyla (BAYRY).
- Follistim AQ Cartridge: A fertility treatment. Competition in the fertility market is fierce, with other options like Gonal-F (MRK) and various IVF procedures.
- Bridion: A neuromuscular blockade reversal agent. Market share varies by region and is subject to hospital formulary decisions. Key competitors are sugammadex biosimilars.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly regulated and competitive, with constant innovation and patent expirations. The women's health segment is growing, fueled by increasing awareness and demand for contraception and fertility treatments. Biosimilars are gaining traction as cost-effective alternatives to biologics.
Positioning
Organon is positioned as a global healthcare company focused on women's health, biosimilars, and established brands. Its strategy involves organic growth, business development, and geographic expansion.
Total Addressable Market (TAM)
The TAM for women's health, biosimilars, and established brands is substantial, estimated to be hundreds of billions of dollars globally. Organon aims to capture a significant share through focused strategies and product development.
Upturn SWOT Analysis
Strengths
- Established global presence
- Diverse product portfolio
- Focus on women's health
- Growing biosimilars business
- Strong cash flow generation from established brands
Weaknesses
- Reliance on established brands facing generic competition
- Debt burden from spin-off
- Integration challenges post spin-off
- Dependence on key products
Opportunities
- Expansion into new geographies
- Acquisition of complementary products and technologies
- Development of innovative women's health solutions
- Increased biosimilar adoption
- Strategic partnerships
Threats
- Generic competition
- Regulatory changes
- Pricing pressures
- Economic downturns
- Product liability litigation
Competitors and Market Share
Key Competitors
- BAYRY
- MRK
- PFE
- VTRS
Competitive Landscape
Organon competes with larger pharmaceutical companies with diversified portfolios. Its focus on women's health and biosimilars provides a niche, but it also faces competition from generic manufacturers for its established brands. Brand recognition, product pipeline, regulatory approvals, and successful execution of business development strategies are very important.
Major Acquisitions
Alydia Health
- Year: 2021
- Acquisition Price (USD millions): 240
- Strategic Rationale: Acquisition of Alydia Health for its innovative treatment for postpartum hemorrhage, enhancing Organon's women's health portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to its success of key offerings such as Nexplanon and its Biosimilars business, plus the management of decline in established brands. Consult financial reports for specifics.
Future Projections: Future projections vary among analysts. Factors that need to be taken into account when building models are growth in Women's Health and Biosimilars as well as the effects of loss of exclusivity in its mature portfolio.
Recent Initiatives: Recent initiatives focus on business development activities, partnerships, and geographic expansion.
Summary
Organon is a pharmaceutical company with a focus on women's health, biosimilars, and established brands. It has a global presence and generates significant cash flow, but faces challenges from generic competition and debt. Opportunities lie in expanding its product portfolio and geographic reach. Organon is trying to expand its market share in Women's Health through acquisitions and its Biosimilars business. The company needs to watch for generic competition which may affect their mature portfolio revenue.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Organon SEC Filings
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Organon & Co
Exchange NYSE | Headquaters Jersey City, NJ, United States | ||
IPO Launch date 2021-06-02 | CEO & Director Mr. Kevin Ali | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 10000 | Website https://www.organon.com |
Full time employees 10000 | Website https://www.organon.com | ||
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.